8-K: FOXO Technologies CEO Mid-Year Update: Growth, Restructuring, and Future Plans

FOXO Technologies Inc. CEO Seamus Lagan provided a mid-year update highlighting operational improvements, corporate restructuring, and strategic growth initiatives including potential acquisitions and a stock exchange uplisting.

Summary

• FOXO Technologies Inc. (FOXO) announced a mid-year update from CEO Seamus Lagan, detailing achievements and future strategies.
• The company has focused on optimizing its healthcare-related businesses, including Myrtle Recovery Centers, Rennova Community Health (Scott County Community Hospital), and Vector BioSource.
• Key corporate actions in the first half of 2026 included addressing legacy liabilities, effecting a 1:3,000 reverse stock split, and resolving issues with former CEO Jon Sabes regarding epigenetics technology.
• FOXO exchanged approximately $7.8 million in Series A Convertible Preferred Stock into non-convertible debt to reduce dilution.
• A 7.5% annual dividend (2.5% cash, 5% stock) was declared for Series E Preferred Stock, issued for the Vector Biosource acquisition, with plans to list this stock separately for acquisitions or capital raises.
• The company is exploring an uplisting to NYSE American or a similar exchange by the end of 2026 and is consulting with investment bankers for this and potential capital raising.
• Myrtle Recovery Centers is expanding its inpatient bed capacity and developing a mobile app, Evana, for post-discharge patient monitoring.
• Rennova Community Health (Big South Fork Medical Center) projects significant increases in inpatient and ER/outpatient visits for 2026.
• Vector BioSource is expanding its customer and supplier base and evaluating a significant acquisition expected to add over $10 million in annual revenue.
• The company aims to accelerate growth through organic means and acquisitions, contingent on securing adequate capital.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive update, with clear operational improvements and strategic plans for growth, but tempered by the acknowledged need for significant capital and the inherent risks in executing acquisitions and uplisting.

Positives

• Reported net revenues of approximately $5.1 million for Q1 2026, up from $3.2 million in Q1 2025.
• Reduced loss from operations to $0.3 million in Q1 2026, a significant improvement from $1.5 million in Q1 2025.
• Myrtle Recovery Centers' Oneida facility operates at 92% occupancy (average daily census of 27.6), with plans to expand from 30 to 32 inpatient beds in July 2026.
• Myrtle's annualized patient admissions are projected at approximately 700 for 2026, a substantial increase from 195 in 2024 and 566 in 2025.
• Rennova Community Health (Big South Fork Medical Center) projects significant increases in inpatient admissions (400 vs. 313 in 2025) and swing bed admissions (65 vs. 37 in 2025) for 2026.
• The hospital is in-network with all major payors, including Medicare Advantage and Tennessee Medicaid.
• Vector BioSource is evaluating a significant acquisition expected to add over $10 million in annual revenues.
• Resolution of legacy liabilities and agreements with former CEO Jon Sabes, including a royalty agreement for epigenetics IP.
• Exchange of approximately $7.8 million in Series A Preferred Stock into debt, reducing potential future dilution.

Negatives

• The company has had limited access to new capital in 2026, hindering growth acceleration.
• The company has a history of losses and may not achieve or maintain profitability in the future.
• The potential acquisition for Vector BioSource is not guaranteed to be completed.
• The uplisting to a recognized stock exchange is not certain.
• The company's Series E Preferred Stock has a security interest in Foxo Acquisitions Corp., indicating potential financial strain or collateralization.

Risks

• Risks associated with changes in the competitive and highly regulated healthcare and pharmaceutical services industries.
• Variations in operating performance across competitors.
• Changes in laws and regulations affecting FOXO's business.
• The ability to implement FOXO's business plans, forecasts, and other expectations.
• The ability to obtain necessary financing for growth and acquisitions.
• The enforceability of FOXO's intellectual property, including patents, and potential infringement on others' IP rights.
• Downturns and a changing regulatory landscape in the highly competitive industries in which FOXO operates.
• The risk that the potential acquisition for Vector BioSource may not be completed.
• Uncertainty regarding the successful uplisting of Class A common stock to a recognized exchange.
• Potential future dilution if the option to acquire majority ownership of the subsidiary related to epigenetics IP is exercised by LongevityFP Technologies, LLC.

Future Outlook

The company is focused on optimizing its existing healthcare operations, exploring internal growth opportunities, and pursuing strategic acquisitions. Plans include an uplisting to a major stock exchange by year-end 2026 and evaluating capital raising alternatives to finance growth and acquisitions. The company anticipates that successful capital raises and uplisting will enable it to become self-sustainable and deliver shareholder value.

Management Comments

• "Our acquisitions in mid-2024 of both Myrtle Recovery Centers, Inc. and Rennova Community Health, Inc. (including its principal subsidiary, Scott County Community Hospital, Inc.) and Vector BioSource, Inc. (Vector) in late 2025 have led to the creation of a diverse, synergistic portfolio of healthcare-related businesses that provide both stability and future growth opportunities."
• "This year, we have focused on optimizing our operating entities as well as addressing several corporate-level issues which have now been resolved."
• "We remain optimistic in our operating subsidiaries and are looking intently at augmenting organic growth with acquisitions."
• "It is hoped that achievements in the first half of the year and plans to up-list to a recognized stock exchange can remove this limitation and facilitate adequate capital to accelerate organic growth and acquisitions to where the Company becomes self-sustainable and delivers value for our shareholders."

Industry Context

StockSavvy.ai notes that FOXO Technologies is navigating a complex healthcare landscape, characterized by consolidation and the increasing importance of specialized services like behavioral health and biospecimen sourcing. The company's strategy of acquiring and optimizing synergistic businesses aligns with industry trends, but its reliance on external capital for further expansion highlights the capital-intensive nature of this sector.

Comparison to Industry Standards

• Myrtle Recovery Centers' occupancy rate of 92% is strong, particularly for a facility that opened in August 2023, indicating effective demand management and service delivery in the substance use disorder treatment market.
• Rennova Community Health's projected increases in admissions and visits suggest it is capturing market share or benefiting from increased healthcare demand in its service area, aiming to improve upon its status as a Critical Access Hospital.
• The projected $10+ million revenue addition from a single acquisition at Vector BioSource, if realized, would represent a significant scaling event for the biospecimen sourcing business, a sector that is crucial for pharmaceutical and biotech R&D.
• The company's efforts to uplist to a major exchange are common for companies seeking to improve liquidity and access a broader investor base, a standard practice for growth-oriented firms in the healthcare sector.

Corporate Governance

Legal Proceedings

• Resolution of legacy issues between former CEO Jon Sabes and the Company, as part of the agreement concerning epigenetics technology development.

Related Party Transactions

• Agreement with former CEO Jon Sabes and FOXO Labs, Inc. concerning epigenetics technology.
• Granting of an exclusive, worldwide license to LongevityFP Technologies, LLC (a company owned by Mr. Sabes) to commercialize the Company's epigenetics intellectual property portfolio.
• Granting of an exclusive, irrevocable ten-year option to LongevityFP Technologies, LLC to acquire majority ownership of the subsidiary holding the epigenetics IP.

Stakeholder Impact

• Shareholders: Potential for increased value through operational improvements, acquisitions, and stock uplisting, but also risk of dilution if preferred stock options are exercised and continued losses.
• Employees: Continued operations and potential expansion of Myrtle Recovery Centers and Rennova Community Health may lead to job stability or creation.
• Creditors: Exchange of convertible preferred stock into debt may alter the company's debt structure and obligations.
• Investors: The reverse stock split aims to improve liquidity and attract institutional investors. The potential uplisting could increase accessibility and trading volume.

Next Steps

• Expand Myrtle Recovery Centers' inpatient bed capacity from 30 to 32 beds, expected in July 2026.
• Launch the Evana mobile application to connect post-discharge patients with care professionals.
• Secure adequate capital to fund additional facility acquisitions for Rennova Community Health.
• Complete a significant acquisition for Vector BioSource, expected in the second half of 2026.
• Uplist Class A common stock to NYSE American or another recognized stock exchange before the end of 2026.
• Engage with Investment Bankers to advise on the planned uplisting and evaluate capital raising alternatives.

Key Dates

Recommendation

The filing indicates positive operational trends and strategic initiatives for growth, including revenue increases and reduced losses. However, the company's reliance on future capital raises, the uncertainty of a stock exchange uplisting, and a history of losses suggest that while there are positive developments, significant risks remain. A 'hold' recommendation reflects a balanced view, awaiting further clarity on capital acquisition and successful execution of growth strategies before considering a more aggressive stance.

Keywords

FOXO Technologies, 8-K Filing, Mid-Year Update, Healthcare, Myrtle Recovery Centers, Rennova Community Health, Scott County Community Hospital, Vector BioSource, Epigenetics, Seamus Lagan, Corporate Governance, Financial Update, Acquisitions, Capital Raise, Stock Uplisting